Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

EP: 1.The Evolving Landscape of Newly Diagnosed Multiple Myeloma

EP: 2.Highlights from ASH 2023 in Transplant-Eligible NDMM

EP: 3.Advances in the Treatment of High-Risk MM

EP: 4.Role of Transplant and MRD in Newly Diagnosed MM

EP: 5.The Evolving Treatment Paradigm for Transplant Ineligible MM

EP: 6.Treatment of Multiple Myeloma at Early Relapse

EP: 7.Potential Role for CAR T-Cell Therapy in MM at Early Relapse

EP: 8.Updates on BCMA-Targeting Bispecifics in MM

Now Viewing

EP: 9.Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

EP: 10.Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

EP: 11.Adverse Effects Related to Bispecifics in Multiple Myeloma

EP: 12.GPRC5D-Targeting Bispecifics in Multiple Myeloma

EP: 13.CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

EP: 14.Treatment Considerations and Sequencing in Multiple Myeloma

This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.

The discussion focuses on real-world data with B-cell maturation antigen (BCMA)–targeted bispecific antibodies, which confirms safety and efficacy in patient populations underrepresented in registration trials, such as non-Hispanic African Americans. Nearly half of real-world patients also had extramedullary disease. However, follow-up is still limited in real-world analyses.

In terms of BCMA-directed therapy sequencing, Abonour notes preferentially using a BCMA bispecific first in BCMA-naive patients, while Krishnan and Usmani counter that they would likely start with BCMA-directed chimeric antigen receptor T-cell therapy initially.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.